The United States government has embarked on a pilot program utilizing artificial intelligence to streamline and inform insurance-coverage decisions, a move lauded by some as a potential solution to a long-standing healthcare quagmire, yet simultaneously drawing significant skepticism and concern from patient advocates and medical professionals who fear it could exacerbate existing challenges. This initiative, spearheaded by the Trump administration through the Centers for Medicare and Medicaid Services (CMS), aims to leverage AI’s analytical power to curb wasteful and inappropriate medical spending, particularly within original Medicare. However, the integration of AI into the often-contentious process of prior authorization raises critical questions about patient access to care, algorithmic transparency, and the delicate balance between cost efficiency and clinical necessity.
The Enduring Challenge of Prior Authorization
For many Americans, the concept of prior authorization (PA) is synonymous with bureaucratic hurdles and frustrating delays in receiving physician-recommended medical care. This administrative requirement, where healthcare providers must obtain approval from a health insurer before a service or prescription is rendered, has become a significant source of contention within the healthcare system. Personal accounts abound regarding the arduous journeys patients and their families undertake to secure coverage for essential medications, complex medical procedures, and even basic diagnostic tests. These "tribulations," as they are often described, highlight a system frequently criticized for its opaqueness and the potential for care delays.
The original intent of prior authorization was to serve as a vital check on healthcare overuse and spending, ensuring that patients received medically appropriate and cost-effective treatments, steering them away from more expensive alternatives when equally efficacious options existed. When used judiciously, PA can indeed play a role in managing healthcare costs and promoting efficient resource allocation. However, its implementation has frequently fallen short of this ideal. A large majority of physicians, as evidenced by surveys from organizations like the American Medical Association (AMA), consistently voice concerns about significant care delays directly attributable to PA requirements. These delays can have severe consequences, leading patients to abandon recommended treatments entirely while awaiting insurer verification of eligibility and medical necessity. Even when care is initially denied, the appeal process, while available, demands additional time and resources, further prolonging access to potentially critical interventions.
The scope of this burden is substantial. In Medicare Advantage, the privately run alternative to original Medicare that now enrolls approximately 55 percent of Medicare-eligible seniors and disabled individuals, insurers issue millions of full or partial claim denials annually based on prior authorization. Federal government reports, including those from the HHS Office of Inspector General (OIG), have documented instances where Medicare Advantage plans have rejected requests for skilled nursing and rehabilitation admissions, raising serious questions about the appropriateness of these initial denials. Erecting such obstacles to medically appropriate care is viewed by many as a particular area of concern, undermining the fundamental promise of health insurance.
A newly released Commonwealth Fund survey conducted in 2025 revealed the widespread impact of these denials. Roughly one in five American working-age adults with private insurance reported that they or a family member had been denied coverage for physician-recommended medical care. Among those who experienced a prior authorization denial, a staggering 41 percent reported a delay in their care, and more than a quarter indicated that their health problem worsened as a direct result. These statistics underscore the profound human cost associated with a cumbersome and often opaque prior authorization process.
The AI Promise: Expedited Claims or Enhanced Denials?
Amidst this backdrop of systemic frustration, the advent of artificial intelligence offers a tantalizing prospect for reform. With its unparalleled ability to efficiently process and analyze vast quantities of information, AI could theoretically expedite the approval of unambiguously allowable claims. By automating the review of straightforward cases, AI holds the potential to significantly reduce care delays, lighten the administrative load on healthcare providers, and free up human reviewers to focus on more complex or nuanced cases. This vision, if realized, could transform prior authorization from a bottleneck into a streamlined gateway to necessary care.
However, the integration of AI into prior authorization is not without its detractors and significant resistance. Critics argue that AI, while efficient, may also increase wrongful denials of health insurance coverage, particularly if algorithms are designed or trained with an emphasis on cost containment over patient well-being. A 2025 American Medical Association survey of physicians highlighted these anxieties, with a substantial 61 percent expressing concern that AI tools would exacerbate denials of treatments they deemed medically necessary. The core worry is that AI might become an automated "gatekeeper," capable of denying care at an unprecedented speed and scale, without the clinical judgment and empathy inherent in human review.
Health policy analysts like Camm Epstein articulate this concern succinctly, stating that "AI should be used to make appropriate care easier to approve, not necessary care easier to deny." This sentiment encapsulates the ethical dilemma at the heart of AI’s application in healthcare: will it serve as a tool to facilitate access or a mechanism to restrict it? The AMA has actively advocated for robust safeguards, demanding that insurers provide detailed clinical reasoning to justify any denial of coverage and calling for greater transparency regarding the inner workings of AI algorithms used in these decisions. Physician oversight, they argue, must remain paramount to ensure that technology serves clinical needs, not financial imperatives alone.
A Chronology of Reforms and the Rise of AI in Medicare
The journey toward reforming prior authorization has seen several key policy shifts and industry pledges over recent years.
- 2024 (Biden Administration): A significant rule was issued by former President Joe Biden’s administration, specifically targeting reforms to reduce delays for patients enrolled in government-run health plans and to streamline the PA process for physicians. This rule mandated that insurers make prior authorization decisions within 72 hours for urgent requests and seven calendar days for non-urgent requests. These critical timeline requirements officially went into effect on January 1 of this year for most public sector health plans, including Medicare Advantage, Medicaid, and plans on the Affordable Care Act (ACA) marketplaces.
- Last Year (Trump Administration and Insurers): In a separate but related effort, the Trump administration, in conjunction with major insurers, pledged to further streamline and accelerate prior authorization processes. Private insurance companies made commitments to standardize electronic requests by 2027 and to actively "reduce the volume of medical services subject to prior authorization" by 2026. This included a focus on common procedures such as colonoscopies and cataract surgeries, signaling an acknowledgment of the widespread burden.
The most recent and significant development is the Trump administration’s initiative to expand the use of AI in prior authorization protocols through the Wasteful and Inappropriate Service Reduction (WISeR) Model. Launched this year by the Centers for Medicare and Medicaid Services (CMS), WISeR is a demonstration project designed to reduce waste and fraud specifically within original Medicare. This represents a notable shift, as prior authorization, while extensively used in Medicare Advantage, has historically been rarely deployed in original Medicare.
The WISeR model, which is set to run through December 2031 across six pilot states, combines advanced technologies such as machine learning with human clinical review. Its focus is on evaluating services that CMS believes are particularly vulnerable to overuse, fraud, and abuse. Initial targets include complex and often costly interventions like skin and tissue substitutes, electrical nerve stimulator implants, and knee arthroscopy for knee osteoarthritis. CMS asserts that by integrating AI, the WISeR model will "ensure timely and appropriate Medicare payment for select items and services."
The WISeR Model: Controversy and Early Feedback
Despite CMS’s stated goals, the WISeR model has rapidly become a focal point of controversy. Critics argue that the introduction of AI-driven prior authorization into original Medicare, a system traditionally more insulated from such administrative hurdles, might not ultimately benefit patients.
A key point of contention revolves around the financial incentives embedded within the WISeR model. Vendors participating in the project, who are contracted to carry out the AI-driven prior authorization reviews, earn a share of what CMS terms "averted expenditures." This payment structure raises serious ethical questions, as it could be interpreted as creating a profit motive for rejecting care requests. This incentive model fuels long-standing concerns within the healthcare reform community regarding profit-making based on discouraging or denying medically necessary care. Several lawmakers have already responded to these concerns, introducing resolutions and amendments aimed at blocking funding for the WISeR model, citing potential threats to patient access.
Early feedback and investigations have also painted a concerning picture. Wendell Potter, a prominent advocate for health insurance reform and former Cigna executive, has documented political pushback against the model. Similarly, Zena Wolf, a researcher with the Center for Health & Democracy, has cited investigations by major news outlets such as the Washington Post, KFF Health News, and the Seattle Times. These reports suggest that in its initial months, the WISeR model has already led to care delays and denials in some instances across the six pilot states. Furthermore, despite the promise of automation, healthcare providers are reportedly experiencing a high administrative burden, including additional work required to appeal denials. This suggests that AI, rather than alleviating the administrative load, may simply be shifting or intensifying it in new ways.
Official Responses and Industry Commitments
The Trump administration, while expanding AI’s role in original Medicare, appears to be adopting a somewhat bifurcated approach to prior authorization. Simultaneously, CMS Administrator Mehmet Oz has issued stern warnings to private insurance company executives, particularly those managing Medicare Advantage plans, urging them to ease the burden of prior authorization. His message has been unequivocal: "If you don’t do it yourselves, then we’re going to do it for you," signaling a potential for federal regulatory intervention if the industry fails to self-regulate effectively.
In response to this pressure, and perhaps to preempt further executive action or legislative intervention, health plans have recently released data suggesting compliance with administration demands. An industry-based survey indicated that between June 2025 and April 2026, requests for prior authorization declined by 11 percent. While this reduction in volume is a positive step, it remains unknown whether the actual denial rate has decreased, a crucial metric for evaluating the true impact on patient access. As KFF has noted, public prior authorization data often remains "short on insight" regarding these critical details.
Furthermore, in a survey conducted last year, all responding health plans affirmed a commitment to not using "AI or algorithms without clinician or practitioner review to deny prior authorization requests that involve medical necessity or clinical considerations." Insurers have also pledged greater transparency regarding the clinical reasoning underpinning their prior authorization decisions. These commitments aim to alleviate concerns about a complete lack of human oversight in AI-driven decisions.
Broader Implications and the Future of AI in Healthcare
The debate surrounding AI in prior authorization underscores a fundamental tension within the American healthcare system: the perpetual struggle to balance cost containment, fraud prevention, and equitable patient access to medically necessary care. While AI offers powerful tools for efficiency and data analysis, its deployment in such a sensitive area raises profound ethical and practical questions.
The "broken system" critique, articulated by figures like physician and Healthcare Huddle founder Jared Dashevsky, posits that current AI implementations risk merely automating a flawed process rather than fundamentally reforming it. Dashevsky suggests that instead of truly "eliminating barriers, reducing administrative waste, [and giving] us more time with patients," AI is being deployed in an "arms race to deny faster and appeal faster." This perspective warns against simply layering technology onto a system that, in its current form, many believe "shouldn’t exist."
The future trajectory of AI in prior authorization will depend heavily on robust regulatory frameworks that prioritize patient safety and access. This includes mandating stringent transparency requirements for AI algorithms, establishing clear and timely appeal processes, and ensuring meaningful human oversight in all denial decisions. The public’s perception of prior authorization as a "major burden" necessitates that any technological solution truly alleviates this stress, rather than compounding it.
The expansion of prior authorization, particularly AI-driven, into original Medicare is a significant policy shift with potentially far-reaching consequences for millions of beneficiaries. As the WISeR model progresses through its pilot phase, rigorous, independent evaluation will be crucial to determine whether AI can genuinely serve as a force for good in healthcare administration, facilitating timely and appropriate care, or if it will inadvertently create new barriers, worsening an already challenging landscape for patients and providers alike. The ultimate success or failure of this ambitious integration will profoundly shape the role of artificial intelligence in the future of healthcare.
Leave a Reply